GSK Presents New Oncology Pipeline Data at ESMO
The pharmaceutical company revealed clinical progress on targeted cancer therapies at the 2026 ESMO conference.
Updated on Oct. 16, 2026 in Cancer
Live Poll
Do you trust that large pharmaceutical companies are successfully prioritizing better outcomes for cancer patients?
GSK showcased its latest oncology developments at the 2026 European Society for Medical Oncology (ESMO) conference. The presentation highlighted advancements in pipeline candidates and strategic licensing agreements for specialized cancer treatments.
Why it matters
GSK focuses its research efforts on developing new medicines for cancers where patients currently face limited treatment options, resistance, or poor clinical outcomes. This strategy aims to address significant unmet medical needs in global oncology care.
The investigational agent Mo-Rez features a drug-to-antibody ratio of 6. Meanwhile, an estimated 80,000 to 120,000 patients are diagnosed with GIST worldwide annually, with 90% of those patients developing secondary KIT mutations.
The players
GSK
A British multinational pharmaceutical and biotechnology company that focuses on research and development in vaccines, specialty medicines, and general medicines.
Hansoh Pharma
A major Chinese pharmaceutical company specializing in the research, development, and manufacture of oncology and central nervous system drugs.
The details
GSK has secured exclusive worldwide rights, excluding specific Asian territories, for the investigational therapies Ris-Rez and Mo-Rez through a partnership with Hansoh Pharma. Additionally, the company continues to manage the development of Jemperli, building on a licensing agreement originally signed in 2014.
Timeline
March 2014: Original Jemperli licensing agreement signed.
2026: GSK presented its updated oncology pipeline at the ESMO conference.
The Big Picture
This presentation follows the standard industry pattern for data disclosure at the European Society for Medical Oncology (ESMO) scientific conference. Such forums serve as the primary global venue for pharmaceutical companies to update the medical community on clinical progress.
These clinical advancements provide hope for patients facing treatment resistance in conditions like GIST or endometrial cancer. Patients should consult with their oncologists to understand how evolving targeted therapies may eventually offer new treatment pathways.
The takeaway
GSK continues to prioritize the development of targeted therapies to combat difficult-to-treat cancer mutations. The expansion of its pipeline through strategic licensing suggests a long-term commitment to addressing high-mortality cancer types.
Further reading
For more on the latest research in the field, explore the Cancer section.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you trust that large pharmaceutical companies are successfully prioritizing better outcomes for cancer patients?
